These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 28040794)
41. Nogo-A expression in oligodendroglial tumors. Jung TY; Jung S; Lee KH; Cao VT; Jin SG; Moon KS; Kim IY; Kang SS; Kim HS; Lee MC Neuropathology; 2011 Feb; 31(1):11-9. PubMed ID: 20487307 [TBL] [Abstract][Full Text] [Related]
42. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Mishima K; Kato Y; Kaneko MK; Nishikawa R; Hirose T; Matsutani M Acta Neuropathol; 2006 May; 111(5):483-8. PubMed ID: 16596424 [TBL] [Abstract][Full Text] [Related]
43. Functional significance of Wnt inhibitory factor-1 gene in kidney cancer. Kawakami K; Hirata H; Yamamura S; Kikuno N; Saini S; Majid S; Tanaka Y; Kawamoto K; Enokida H; Nakagawa M; Dahiya R Cancer Res; 2009 Nov; 69(22):8603-10. PubMed ID: 19887605 [TBL] [Abstract][Full Text] [Related]
44. Molecular pathways in the formation of gliomas. von Deimling A; Louis DN; Wiestler OD Glia; 1995 Nov; 15(3):328-38. PubMed ID: 8586467 [TBL] [Abstract][Full Text] [Related]
45. Estrogen receptor beta (ERbeta) protein expression correlates with BAG-1 and prognosis in brain glial tumours. Batistatou A; Kyzas PA; Goussia A; Arkoumani E; Voulgaris S; Polyzoidis K; Agnantis NJ; Stefanou D J Neurooncol; 2006 Mar; 77(1):17-23. PubMed ID: 16292491 [TBL] [Abstract][Full Text] [Related]
46. Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma. Gupta M; Djalilvand A; Brat DJ Am J Clin Pathol; 2005 Nov; 124(5):755-68. PubMed ID: 16203285 [TBL] [Abstract][Full Text] [Related]
47. The Expression of Leptin and Its Receptor During Tumorigenesis of Diffuse Gliomas such as Astrocytoma and Oligodendroglioma- Grade II, III and IV (NOS). Vokuda RS; B H S; Madhugiri VS; Velusamy SK; Verma SK Asian Pac J Cancer Prev; 2019 Feb; 20(2):479-485. PubMed ID: 30803210 [TBL] [Abstract][Full Text] [Related]
48. [THE STUDY OF THE ORIGIN OF HUMAN GLIOMA BASED ON CELL LINES AND TUMOR SPECIMENS]. Timin GV; Lakhina YS; Gulyaev DA; Tolkunova EN Tsitologiia; 2015; 57(12):893-8. PubMed ID: 26995968 [TBL] [Abstract][Full Text] [Related]
49. Expression and distribution of id helix-loop-helix proteins in human astrocytic tumors. Vandeputte DA; Troost D; Leenstra S; Ijlst-Keizers H; Ramkema M; Bosch DA; Baas F; Das NK; Aronica E Glia; 2002 Jun; 38(4):329-38. PubMed ID: 12007145 [TBL] [Abstract][Full Text] [Related]
50. Shared epigenetic mechanisms in human and mouse gliomas inactivate expression of the growth suppressor SLC5A8. Hong C; Maunakea A; Jun P; Bollen AW; Hodgson JG; Goldenberg DD; Weiss WA; Costello JF Cancer Res; 2005 May; 65(9):3617-23. PubMed ID: 15867356 [TBL] [Abstract][Full Text] [Related]
51. Identification of cadherin-11 down-regulation as a common response of astrocytoma cells to transforming growth factor-alpha. Zhou R; Skalli O Differentiation; 2000 Dec; 66(4-5):165-72. PubMed ID: 11269942 [TBL] [Abstract][Full Text] [Related]
52. Expression of the genes encoding myelin basic protein and proteolipid protein in human malignant gliomas. Golfinos JG; Norman SA; Coons SW; Norman RA; Ballecer C; Scheck AC Clin Cancer Res; 1997 May; 3(5):799-804. PubMed ID: 9815752 [TBL] [Abstract][Full Text] [Related]
53. Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors. Lu QR; Park JK; Noll E; Chan JA; Alberta J; Yuk D; Alzamora MG; Louis DN; Stiles CD; Rowitch DH; Black PM Proc Natl Acad Sci U S A; 2001 Sep; 98(19):10851-6. PubMed ID: 11526205 [TBL] [Abstract][Full Text] [Related]
54. Loss of tuberin from cerebral tissues with tuberous sclerosis and astrocytoma. Mizuguchi M; Kato M; Yamanouchi H; Ikeda K; Takashima S Ann Neurol; 1996 Dec; 40(6):941-4. PubMed ID: 9007104 [TBL] [Abstract][Full Text] [Related]
55. Expression of PROX1 Is a common feature of high-grade malignant astrocytic gliomas. Elsir T; Eriksson A; Orrego A; Lindström MS; Nistér M J Neuropathol Exp Neurol; 2010 Feb; 69(2):129-38. PubMed ID: 20084020 [TBL] [Abstract][Full Text] [Related]
56. Expression of the constitutively activated RelA/NF-kappaB in human astrocytic tumors and the in vitro implication in the regulation of urokinase-type plasminogen activator, migration, and invasion. Tsunoda K; Kitange G; Anda T; Shabani HK; Kaminogo M; Shibata S; Nagata I Brain Tumor Pathol; 2005; 22(2):79-87. PubMed ID: 18095109 [TBL] [Abstract][Full Text] [Related]
57. Cytokeratin immunoreactivity in gliomas. Ng HK; Lo ST Histopathology; 1989 Apr; 14(4):359-68. PubMed ID: 2472343 [TBL] [Abstract][Full Text] [Related]
58. DLC2/StarD13 plays a role of a tumor suppressor in astrocytoma. El-Sitt S; Khalil BD; Hanna S; El-Sabban M; Fakhreddine N; El-Sibai M Oncol Rep; 2012 Aug; 28(2):511-8. PubMed ID: 22614672 [TBL] [Abstract][Full Text] [Related]
59. Alpha-actinin 1 and alpha-actinin 4: contrasting roles in the survival, motility, and RhoA signaling of astrocytoma cells. Quick Q; Skalli O Exp Cell Res; 2010 Apr; 316(7):1137-47. PubMed ID: 20156433 [TBL] [Abstract][Full Text] [Related]